LH heads into its July 30 earnings print with options markets flashing unusually bullish conviction — a sharp break from the defensive tone that dominated for much of the past two months.
The shift in options positioning is the most striking feature of the current setup. The put/call ratio has collapsed to 0.31, more than 1.6 standard deviations below its 20-day average of 0.98. Through June and into mid-July, the ratio was running comfortably above 1.0, with readings as high as 1.70 in late June. The pivot to call-heavy activity over the past week coincides with a 15% stock rally over the past month to $296.77 — options traders are no longer hedging; they are reaching for upside into the number. The borrow market reinforces the message: availability is deep at roughly 1,355% of short interest, meaning there are more than thirteen shares available to borrow for every one currently shorted. Borrowing costs are low at 0.44%. There is no meaningful squeeze pressure, no aggressive new short-building.
Short interest itself has also been retreating. Bears have steadily covered over the past month — SI has fallen nearly 19% and now represents just 3.4% of the free float, down from levels closer to 4.2% in mid-June. The short score drifted lower through July, settling near 39, a mid-range reading that reflects neither urgency nor conviction from the bear camp. The retreat in SI alongside the stock's rally tells a consistent story: sellers have not found traction, and fewer are trying.
The analyst community has grown more constructive in the run-up. B of A Securities raised its target to $320 from $300 in mid-July, maintaining its Buy rating. Baird similarly lifted to $338 from $335 on an Outperform. The consensus mean target of around $312 sits modestly above the current price, leaving limited implied upside at face value — but the direction of travel has been upward across most desks. Bulls anchor on the 7.5% Central Lab revenue growth driven by trial wins and AI-powered pathology tools, plus an 8.9% gain in the Diagnostics segment and a backlog of $8.71 billion with a book-to-bill of 1.11x. Bears push back on PAMA reimbursement risk, acquisition integration friction, and total requisitions that have recently missed growth targets — a signal that organic volume momentum may be softer than the headline numbers suggest.
Among peers, closest comparable DGX gained more than 8% on the week, giving the diagnostic space a broadly supportive backdrop into LH's report. GH and CYH underperformed, down 5.5% and 17% respectively, highlighting that the sector narrative is not uniform. Historically, LH's past two prints produced muted reactions — a 1% gain after May results and essentially flat after the April report — suggesting the stock has not been a large-move name in recent quarters. The July 30 release will test whether the Central Lab and Diagnostics growth narrative holds its pace, and whether management can credibly address the reimbursement and volume concerns that keep a portion of the Street on the sidelines.
See the live data behind this article on ORTEX.
Open LH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
